Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $44.25 Average Target Price from Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been given a consensus recommendation of “Moderate Buy” by the eleven brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $44.25.

Several research analysts have recently issued reports on STOK shares. Wedbush raised their target price on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Guggenheim reissued a “buy” rating and set a $60.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Canaccord Genuity Group cut their price objective on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Chardan Capital reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Finally, JPMorgan Chase & Co. began coverage on shares of Stoke Therapeutics in a report on Friday, August 21st. They set an “overweight” rating and a $40.00 target price for the company.

Stoke Therapeutics Stock Down 1.3%

Shares of STOK opened at $30.50 on Friday. The stock’s fifty day simple moving average is $31.23 and its 200-day simple moving average is $32.23. The firm has a market capitalization of $1.97 billion, a PE ratio of -9.13 and a beta of 1.23. Stoke Therapeutics has a 12-month low of $18.80 and a 12-month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%.The firm had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. Analysts anticipate that Stoke Therapeutics will post -3.52 EPS for the current year.

Insider Transactions at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 12,567 shares of Stoke Therapeutics stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $402,521.01. Following the completion of the sale, the director directly owned 124,557 shares of the company’s stock, valued at $3,989,560.71. The trade was a 9.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 7,176 shares of Stoke Therapeutics stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $29.04, for a total value of $208,391.04. Following the sale, the insider directly owned 20,422 shares of the company’s stock, valued at approximately $593,054.88. This trade represents a 26.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 28,828 shares of company stock worth $898,874 in the last three months. Insiders own 9.60% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC raised its position in shares of Stoke Therapeutics by 1.2% in the 4th quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock valued at $935,000 after acquiring an additional 354 shares during the period. Versant Capital Management Inc boosted its stake in Stoke Therapeutics by 22.6% during the 2nd quarter. Versant Capital Management Inc now owns 1,951 shares of the company’s stock worth $64,000 after acquiring an additional 359 shares during the last quarter. Strs Ohio grew its holdings in Stoke Therapeutics by 9.4% during the fourth quarter. Strs Ohio now owns 7,000 shares of the company’s stock valued at $222,000 after purchasing an additional 600 shares during the period. First Trust Advisors LP grew its holdings in Stoke Therapeutics by 0.5% during the first quarter. First Trust Advisors LP now owns 163,459 shares of the company’s stock valued at $5,322,000 after purchasing an additional 780 shares during the period. Finally, Kestra Advisory Services LLC bought a new stake in Stoke Therapeutics in the fourth quarter valued at approximately $26,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.